Literature DB >> 9719467

Cytokines and their roles in pancreatic islet beta-cell destruction and insulin-dependent diabetes mellitus.

A Rabinovitch1, W L Suarez-Pinzon.   

Abstract

Insulin-dependent diabetes mellitus (IDDM) is a disease that results from autoimmune destruction of the insulin-producing beta-cells in the pancreatic islets of Langerhans. The autoimmune response against islet beta-cells is believed to result from a disorder of immunoregulation. According to this concept, a T helper 1 (Th1) subset of T cells and their cytokine products, i.e. Type 1 cytokines--interleukin 2 (IL-2), interferon gamma (IFNgamma), and tumor necrosis factor beta (TNFbeta), dominate over an immunoregulatory (suppressor) Th2 subset of T cells and their cytokine products, i.e. Type 2 cytokines--IL-4 and IL-10. This allows Type 1 cytokines to initiate a cascade of immune/inflammatory processes in the islet (insulitis), culminating in beta-cell destruction. Type 1 cytokines activate (1) cytotoxic T cells that interact specifically with beta-cells and destroy them, and (2) macrophages to produce proinflammatory cytokines (IL-1 and TNFalpha), and oxygen and nitrogen free radicals that are highly toxic to islet beta-cells. Furthermore, the cytokines IL-1, TNFalpha, and IFNgamma are cytotoxic to beta-cells, in large part by inducing the formation of oxygen free radicals, nitric oxide, and peroxynitrite in the beta-cells themselves. Therefore, it would appear that prevention of islet beta-cell destruction and IDDM should be aimed at stimulating the production and/or action of Type 2 cytokines, inhibiting the production and/or action of Type 1 cytokines, and inhibiting the production and/or action of oxygen and nitrogen free radicals in the pancreatic islets.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9719467     DOI: 10.1016/s0006-2952(97)00492-9

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  109 in total

1.  Assessment of ribozyme cleavage efficiency using reverse transcriptase real-time PCR.

Authors:  D Klein; M Denis; C Ricordi; R L Pastori
Journal:  Mol Biotechnol       Date:  2000-03       Impact factor: 2.695

2.  Fatal attraction: chemokines and type 1 diabetes.

Authors:  Mark A Atkinson; S Brian Wilson
Journal:  J Clin Invest       Date:  2002-12       Impact factor: 14.808

Review 3.  Role of cytokines in the pathogenesis of autoimmune diabetes mellitus.

Authors:  Alex Rabinovitch; Wilma L Suarez-Pinzon
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

4.  Cytokines activate genes of the endocytotic pathway in insulin-producing RINm5F cells.

Authors:  K L A Souza; M Elsner; P C F Mathias; S Lenzen; M Tiedge
Journal:  Diabetologia       Date:  2004-07-10       Impact factor: 10.122

5.  Acute cytokine-mediated downregulation of the zinc transporter ZnT8 alters pancreatic beta-cell function.

Authors:  Malek El Muayed; Liana K Billings; Meera R Raja; Xiaomin Zhang; Paul J Park; Marsha V Newman; Dixon B Kaufman; Thomas V O'Halloran; William L Lowe
Journal:  J Endocrinol       Date:  2010-05-27       Impact factor: 4.286

6.  Adenosine receptor activation ameliorates type 1 diabetes.

Authors:  Zoltán H Németh; David Bleich; Balázs Csóka; Pál Pacher; Jon G Mabley; Leonóra Himer; E Sylvester Vizi; Edwin A Deitch; Csaba Szabó; Bruce N Cronstein; György Haskó
Journal:  FASEB J       Date:  2007-04-03       Impact factor: 5.191

7.  Down-regulation of multiple low dose streptozotocin-induced diabetes by mycophenolate mofetil.

Authors:  D Maksimovic-Ivanic; V Trajkovic; D J Miljkovic; M Mostarica Stojkovic; S Stosic-Grujicic
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

8.  Group VIA Phospholipase A2 (iPLA2β) Modulates Bcl-x 5'-Splice Site Selection and Suppresses Anti-apoptotic Bcl-x(L) in β-Cells.

Authors:  Suzanne E Barbour; Phuong T Nguyen; Margaret Park; Bhargavi Emani; Xiaoyong Lei; Mamatha Kambalapalli; Jacqueline C Shultz; Dayanjan Wijesinghe; Charles E Chalfant; Sasanka Ramanadham
Journal:  J Biol Chem       Date:  2015-03-11       Impact factor: 5.157

9.  The novel inosine analogue, INO-2002, protects against diabetes development in multiple low-dose streptozotocin and non-obese diabetic mouse models of type I diabetes.

Authors:  Jon G Mabley; Pal Pacher; Kanneganti G K Murthy; William Williams; Garry J Southan; Andrew L Salzman; Csaba Szabo
Journal:  J Endocrinol       Date:  2008-06-18       Impact factor: 4.286

10.  Fasting and meal-stimulated residual beta cell function is positively associated with serum concentrations of proinflammatory cytokines and negatively associated with anti-inflammatory and regulatory cytokines in patients with longer term type 1 diabetes.

Authors:  M N Pham; H Kolb; T Battelino; J Ludvigsson; P Pozzilli; F Zivehe; M Roden; T Mandrup-Poulsen; N C Schloot
Journal:  Diabetologia       Date:  2013-03-15       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.